Madhu S. Mondal | Senior Director, Toxicology
AbbVie Inc

Dr. Mondal completed Ph. D. from Tata Institute of Fundamental Research (TIFR), Mumbai, India and then continued his postdoctoral research at the Oxford University, England and Harvard University Medical School, USA, in the areas of Molecular Pharmacology and Biomarkers.  After working on toxicity biomarkers in a biotechnology company (LSBC) in Maryland, Dr. Mondal moved to Pfizer Toxicology departments in St. Louis and San Diego from 2002 to 2006. During his 5 years at Pfizer, Dr. Mondal established laboratories for mechanistic toxicology research and guided discovery oncology project teams for the nonclinical safety testing of drug candidates. In 2006, Dr. Mondal joined Novartis Institutes of Biomedical Research Inc. in Cambridge, Massachusetts as the Head of Biochemical Toxicology, working on nonclinical safety assessment of Oncology, Cardiovascular and Infectious disease area assets. Dr. Mondal then joined AstraZeneca in 2012 and was tasked to lead toxicology efforts for Oncology and Infectious disease project teams. In 2017, Dr. Mondal assumed the role of Head of Toxicology and Safety Pharmacology at Forma Therapeutics, located in the Boston area, where he was responsible for developing the nonclinical safety testing strategy for the company. In May 2020, Dr. Mondal joined Cerevel Therapeutics as the Head of Toxicology, Senior Director, leading the Toxicology efforts of all project teams of the company. Currently, Dr, Serves as the Senior Director, Toxicology at AbbVie, Inc. Over the last 24 years, Dr. Mondal has assumed roles of increasing responsibility in the Biotech & Pharmaceutical companies, developing more than #30 candidate drugs at various preclinical or clinical stages, including some that are now approved for marketing in the US and other territories.